Compounds for the degradation of ALK protein

By developing compounds that can target the ALK protein and cross the blood-brain barrier, the challenges of drug resistance in ALK-positive tumors and the treatment of brain metastases in existing treatment methods have been solved, achieving effective degradation of the ALK protein and treatment of systemic and brain tumors.

CN123076593APending Publication Date: 2026-11-10BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580028215.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-17
Filing Date
2025-04-16
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing tyrosine kinase inhibitors have resistance issues when treating ALK-positive tumors, and CELMoD-type protein degraders have difficulty crossing the blood-brain barrier, thus failing to effectively target ALK proteins and treat brain metastases.

Method used

A class of compounds has been developed that can target ALK proteins and cross the blood-brain barrier, degrading them by binding to ALK proteins. These compounds include those with specific structures and their pharmaceutically acceptable salts, solvates, hydrates, cocrystals, cage-like inclusion compounds, polymorphs, or tautomers.

Benefits of technology

It achieves effective degradation of ALK protein, especially in the treatment of brain tumors, overcoming drug resistance problems and providing systemic and brain therapeutic effects against ALK-positive tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076593A_ABST
    Figure CN123076593A_ABST
Patent Text Reader

Abstract

This document provides compounds and compositions thereof that reduce ALK protein levels. In some embodiments, the compounds have the structure of formula -Ia. In some embodiments, the compounds and compositions are provided for treating ALK-related diseases (e.g., cancer). (I).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 635,566, filed April 17, 2024, the disclosure of which is incorporated herein by reference.

[0003] Invention Field

[0004] This disclosure relates to novel anaplastic lymphoma kinase (ALK) degrading agents and methods including the administration of ALK degrading agents, which can be used to treat abnormal cell growth in mammals, particularly humans, such as cancer. Background of the Invention

[0006] The compounds described herein, such as ALK degraders, can be used to prevent and treat the diseases or disorders described herein, such as abnormal cell growth (e.g., the cancers described herein).

[0007] Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first discovered in 1994 as part of a nucleophosphorus protein (NPM)-ALK fusion resulting from a highly relapsed (2;5)(p23;q35) translocation in anaplastic large cell lymphoma (ALCL). Since then, this NPM-ALK fusion and other ALK rearrangements have been identified in both hematopoietic and non-hematopoietic solid tumors. For example, ALK translocations or inversions are common (50–60%) in inflammatory myofibroblastic tumors (IMT) and are present in 4–8% of non-small cell lung cancers (NSCLC). ALK translocations are also present at a lower frequency in diffuse large B-cell lymphoma, breast cancer, and renal cell carcinoma. The fusion proteins resulting from these cytogenetic rearrangements associate the N-terminal portion of a chaperone protein (typically containing a dimerization domain) with the entire intracellular portion of ALK, including its tyrosine kinase domain. Once expressed, the fusion protein dimerizes, causing aberrant constitutive autophosphorylation and activation of ALK kinase, thereby promoting uncontrolled cell proliferation and survival.

[0008] The full-length ALK receptor cDNA was isolated in 1997. During development, ALK is expressed almost exclusively in the central and peripheral nervous systems. In adults, low levels of ALK mRNA expression have been reported in a few restricted areas of the brain, the small intestine (possibly within the enteroperitoneal ganglia), and the testes. Expression of the full-length ALK receptor has also been observed in neuroblastomas, embryonal tumors affecting the peripheral nervous system. ALK kinases in some neuroblastomas are activated due to gain-of-function mutations, ALK gene amplification, or copy number increases. Other solid tumors expressing the full-length ALK receptor include rhabdomyosarcoma, glioblastoma, melanoma, and retinoblastoma. However, the oncogenic role of ALK in these tumors has not been definitively established.

[0009] ALK is associated with a wide variety of tumor types, including anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, breast and renal cell carcinoma, non-small cell lung cancer, and neuroblastoma. This makes ALK an attractive target for cancer therapy. Since ALK-driven tumors rely on constitutively activated ALK kinases for proliferation, various tyrosine kinase inhibitors have been developed to block tumor growth. While some inhibitors are under investigation in clinical trials, others are already approved for treatment, particularly in ALK-positive lung cancer. Their efficacy is significant but time-limited because tumors escape treatment through various mechanisms and develop resistance. Therefore, there is an urgent need to target ALK-dependent tumors with alternative therapeutic strategies, and potentially in combination with kinase inhibitors.

[0010] Anaplastic lymphoma kinase positive (ALK+) accounts for 3-5% of all NSCLC, and 20-40% of patients already have brain metastases at diagnosis. Tyrosine kinase inhibitors can cross the blood-brain barrier (BBB), but due to ALK gene mutations, most patients develop resistance within 1-2 years. CELMoD is a protein degrader with a different binding mode and can overcome ALK mutations, but due to its high polarity, CELMoD has difficulty crossing the BBB. This invention includes CELMoD compounds that target the ALK protein and effectively cross the BBB. Invention Overview

[0012] This specification relates to compounds having the following structures: ; ; ; ; ; ; ;and ; Or a pharmaceutically acceptable salt, solvate, hydrate, eutectic, cage-like inclusion compound, polymorph or tautomer thereof, a pharmaceutically acceptable salt of said polymorph or tautomer, a stereoisomer of any of the foregoing, or a mixture thereof.

[0013] The compounds disclosed herein can be used as pharmaceutical agents and in methods for treating cancer, the methods comprising administering a therapeutically effective amount of the compounds to a mammal suffering from cancer. Invention Details

[0015] As used herein, the terms “comprising” and “including” are used interchangeably. The terms “comprising” and “including” should be interpreted as indicating the presence of the stated features or components mentioned, but do not exclude the presence or addition of one or more features, components, or groups thereof. Furthermore, the terms “comprising” and “including” are intended to include examples covered by the term “consisting of”. Therefore, the term “consisting of” may be used instead of the terms “comprising” and “including” to provide more specific embodiments of the invention.

[0016] The term "composed of" means that the subject matter has at least 90%, 95%, 97%, 98%, or 99% of the features or components of its declared composition. In another embodiment, the term "composed of" excludes any other features or components from any subsequently elaborated scope, except those that are not essential to the desired technical effect.

[0017] As used herein, the term "or" should be interpreted as inclusive "or," meaning any one or any combination thereof. Therefore, "A, B, or C" means any of the following: "A; B; C; A and B; A and C; B and C; A, B, and C." Exceptions to this definition will only occur when combinations of elements, functions, steps, or behaviors are inherently mutually exclusive in some way.

[0018] As stated herein, any concentration range, percentage range, ratio range, or integer range shall be understood to include any integer value within the stated range, and, where appropriate, to include fractions thereof (e.g., one-tenth and one-hundredth of an integer), unless otherwise stated. Furthermore, any numerical ranges stated herein relating to any physical characteristic (e.g., polymer subunits, size, or thickness) shall be understood to include any integer within the stated range, unless otherwise stated. As used herein, the terms “about” and “approximately” mean ±20%, ±10%, ±5%, or ±1% of the range, value, or structure indicated, unless otherwise stated.

[0019] An alkyl group is a group having 1 to 10 carbon atoms (C1-C2). 10Alkyl groups are saturated, partially saturated, or unsaturated straight-chain or branched acyclic hydrocarbons, typically with 1 to 8 carbon atoms (C1-C8 alkyl), or in some embodiments 1 to 6 (C1-C6 alkyl), 1 to 4 (C1-C4 alkyl), 1 to 3 (C1-C3 alkyl), or 2 to 6 (C2-C6 alkyl) carbon atoms. In some embodiments, the alkyl group is a saturated alkyl group. Representative saturated alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyl groups include -isopropyl, -sec-butyl, -isobutyl, tert-butyl, -isopentyl, -neopentyl, tert-pentyl, -2-methylpentyl, -3-methylpentyl, -4-methylpentyl, -2,3-dimethylbutyl, etc. In some embodiments, the alkyl group is an unsaturated alkyl group, also referred to as alkenyl or ynyl. An "alkenyl" group is an alkyl group containing one or more carbon-carbon double bonds. An alkynyl group is an alkyl group containing one or more carbon-carbon triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, -CH2C≡C(CH3), and -CH2C≡C(CH2CH3). Alkyl groups can be substituted or unsubstituted. When alkyl groups are referred to herein as “substituted,” they may be substituted by any one or more of the following substituents: those visible in the exemplary compounds and embodiments disclosed herein, and halogens; hydroxyl; alkoxy; cycloalkoxy, aryloxy, heterocyclic alkoxy, heteroaryloxy, cycloalkylalkoxy, arylalkoxy, heterocyclic alkoxy, heteroarylalkoxy; oxo (=O); amino, alkylamino, cycloalkylamino, arylamino, heterocyclic amino, heteroarylamino, cycloalkylalkylamino, arylalkylamino, heterocyclic alkylamino, heteroarylalkylamino; imino; amide (imido) ); amidine; guanidinium; enamino; acylamino; sulfonylamino; urea, nitrobenzene; oxime; hydroxyamino; alkoxyamino; arylalkoxyamino; hydrazido; hydrazono; azide; nitro; thio (-SH), alkylthio; =S; sulfinyl; sulfonyl; aminosulfonyl; phosphonate; phosphinyl; acyl; formyl; carboxyl; ester; carbamate; amide; cyano; isocyanate; isothiocyanate; cyanoyl; thiocyanate; or -B(OH)2.In some embodiments, when the alkyl groups described herein are referred to as “substituted,” they may be substituted by any one or more of the following substituents: those visible in the exemplary compounds and embodiments disclosed herein, and halogens (chlorine, iodine, bromine, or fluorine); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfonamide; ketone; aldehyde; ester; urea; ethyl carbamate; oxime; hydroxylamine; alkoxyamine; arylalkoxyamine; N-oxide; hydrazine; acylhydrazine; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH)2 or -O(alkyl)aminocarbonyl.

[0020] "Cycloalkyl" groups are groups of 3 to 10 carbon atoms (C3-C4) having a single ring or multiple fused or bridged rings. 10 The cycloalkyl group is a saturated or partially saturated cycloalkyl group, optionally substituted. In some embodiments, the cycloalkyl group has 3 to 8 cyclic carbon atoms (C3-C8 cycloalkyl), while in other embodiments, the number of cyclic carbon atoms is 3 to 5 (C3-C5 cycloalkyl), 3 to 6 (C3-C6 cycloalkyl), or 3 to 7 (C3-C7 cycloalkyl). In some embodiments, the cycloalkyl group is a saturated cycloalkyl group. Such saturated cycloalkyl groups include, by way of example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, etc., or polycyclic or bridged ring structures such as 1-bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, etc. In other embodiments, the cycloalkyl group is an unsaturated cycloalkyl group. Examples of unsaturated cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, hexadienyl, etc. Cycloalkyl groups can be substituted or unsubstituted. Such substituted cycloalkyl groups include, by way of example, cyclohexanol, etc.

[0021] A "heterocyclic group" is a non-aromatic cycloalkyl group in which one to four ring carbon atoms are each independently replaced by a heteroatom selected from O, S, and N. In some embodiments, the heterocyclic group comprises 3 to 10 ring members, while other such groups have 3 to 5, 3 to 6, or 3 to 8 ring members. The heterocyclic group can also be bonded to other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocycle). The heterocyclic alkyl group can be substituted or unsubstituted. The heterocyclic group encompasses saturated and partially saturated ring systems. Furthermore, the term heterocyclic is intended to cover any non-aromatic ring containing at least one heteroatom, which can be fused to an aryl or heteroaryl ring regardless of its connection to the rest of the molecule. This expression also includes bridging polycyclic systems containing heteroatoms. Representative examples of heterocyclic groups include, but are not limited to, acridine, aziridine, aziridine-heptyl, pyrrolidinyl, imidazoalkyl (e.g., imidazoline-4-one or imidazoline-2,4-diketoyl), pyrazolyl, thiazoalkyl, tetrahydrothiophene, tetrahydrofuranyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxothiocyclohexyl, dithiocyclohexyl, 1,4-dioxaspiro[4.5]decyl, homopiperazinyl, quininecycloyl, or tetrahydropyrimidine-2(1H)-one. Representative substituted heterocyclic groups can be monosubstituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups that are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted by multiple substituents (such as those listed below).

[0022] An "aryl" group is a group consisting of 6 to 14 carbon atoms (C6-C5) having a single ring (e.g., phenyl) or multiple fused rings (e.g., naphthyl or anthracene). 14 The aryl group is an aromatic carbocyclic group. In some embodiments, the aryl group contains 6-14 carbons (C6-C5) in the ring moiety of the group. 14 Aryl), and in other embodiments containing 6 to 12 carbons (C6-C5). 12 Aryl groups or even 6 to 10 carbon atoms (C6-C) 10 Aryl groups. Specific aryl groups include phenyl, biphenyl, naphthyl, etc. Aryl groups can be substituted or unsubstituted. The phrase "aryl group" also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.).

[0023] A "heteroaryl" group is an aromatic ring system having 1 to 4 heteroatoms as ring atoms, wherein the remaining atoms are carbon atoms. In some embodiments, the heteroaryl group contains 3 to 6 ring atoms in the ring portion of the group; in other embodiments, it contains 6 to 9 or even 6 to 10 atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. In some embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include, but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazoleyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzo[d]isooxazolyl (e.g., benzo[d]isooxazolyl), thiazolyl, pyrolyl, pyrazinyl, pyrimidinyl, thiophene, benzo[thiophene], furanyl, benzo[furan], indoleyl (e.g., indole-2-one or isoindoline-1-one), azaindolyl (pyrrolopyridyl or 1H-pyrrolo[2,3-b]pyridyl), indazoleyl, benzo[imidazole] (e.g., 1H-benzo[d]... Imidazolyl), imidazopyridyl (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzoxazolyl (e.g., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, isoxazolopyridyl, thianaphthyl, purine, xanthine, adenine, guanine, quinolinyl, isoquinolinyl (e.g., 3,4-dihydroisoquinolin-1(2H)-keto), tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Heteroaryl groups may be substituted or unsubstituted.

[0024] "Halogen" or "halogenated" refers to fluorine, chlorine, bromine, or iodine.

[0025] The "alkoxy" group is -O (alkyl), where alkyl is as defined above.

[0026] The "oxo" group is the "=O" group bonded to carbon.

[0027] The "amino" group is -NH2, and one or both hydrogen atoms can be replaced by alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups.

[0028] The "amide group" is an amide group having the formula -NHC(O)-, in which the hydrogen atom can be replaced by an alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group.

[0029] The "heteroaryl-oxygen" group is -O-(heteroaryl), where the heteroaryl group is as defined above. The "heterocyclic-oxygen" group is -O-(heterocyclic), where the heterocyclic group is as defined above. The "cycloalkyl-oxygen" group is -O-(cycloalkyl), where the cycloalkyl group is as defined above.

[0030] When the groups described herein (excluding alkyl, amino, and amide groups) are referred to as “substituted,” they may be substituted by any suitable one or more substituents. Exemplary examples of substituents are those visible in the exemplary compounds and embodiments disclosed herein, as well as halogens (chlorine, iodine, bromine, or fluorine); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfonamide; ketone; aldehyde; ester; urea; ethyl carbamate; oxime; hydroxylamine; alkoxyamine; arylalkoxyamine; N-oxide; hydrazine; acylhydrazine; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxo (=O); B(OH)2, -O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused. The group may be a non-fused polycyclic group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclic group, which may be a monocyclic or fused or non-fused polycyclic group (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); a monocyclic or fused or non-fused polycyclic aryl or heteroaryl group (e.g., phenyl, naphthyl, pyrrolidinyl, indolyl, furanyl, thiophene, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridineyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophene, or benzofuranyl); cycloalkoxy, aryloxy, heterocyclic oxy, heteroaryloxy, cycloalkylalkoxy, arylalkoxy, heterocyclic alkoxy, and heteroarylalkoxy.

[0031] Embodiments of this disclosure are intended to cover pharmaceutically acceptable salts, tautomers, isotopic isomers, and stereoisomers of the compounds provided herein (such as those of the present invention).

[0032] As used herein, the term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base (including inorganic acids and inorganic bases, as well as organic acids and organic bases). Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include, but are not limited to, metal salts prepared from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc, or organic salts prepared from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucosamine), and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids, such as acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, vinylsulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, viscous acid, nitric acid, dihydroxynaphthyl acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, p-aminobenzenesulfonic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. Specific non-toxic acids include hydrochloric acid, hydrobromic acid, maleic acid, phosphoric acid, sulfuric acid, and methanesulfonic acid. Therefore, specific examples of salts include hydrochloride salts, formate salts, and methanesulfonate salts. Other salts are well known in the art; see, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19th edition, Mack Publishing, Easton PA (1995).

[0033] As used herein and unless otherwise stated, the terms "stereoisomer" or "stereoisomer-pure" refer to a stereoisomer of a particular compound that is substantially free of other stereoisomers of the compound. For example, a stereoisomer-pure compound having one chiral center will be substantially free of its opposite enantiomers. A stereoisomer-pure compound having two chiral centers will be substantially free of its other diastereomers. Typical stereoisomer-pure compounds contain more than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of other stereoisomers of the compound, more than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of other stereoisomers of the compound, or more than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of other stereoisomers of the compound. The compounds disclosed herein may have a chiral center and may exist as racemates, individual enantiomers, diastereomers, or mixtures thereof. All such isomers are included in the embodiments disclosed herein, including mixtures thereof.

[0034] The use of the stereoisomers of the compounds disclosed herein, as well as mixtures of those forms, is covered in the embodiments disclosed herein. For example, mixtures containing equal or unequal amounts of enantiomers of a particular compound can be used in the methods and compositions disclosed herein. These isomers can be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, for example, Jacques, J. et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, SH, et al., Tetrahedron 33:2725 (1977); Eliel, EL, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH, Tables of Resolving Agents and OpticalResolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972); Todd, M., Separation Of Enantiomers: Synthetic Methods (Wiley-VCHVerlag GmbH & Co. KgaA, Weinheim, Germany, 2014); Toda, F., EnantiomerSeparation: Fundamentals and Practical Methods (Springer Science & BusinessMedia, 2007); Subramanian, G. Chiral Separation Techniques: A PracticalApproach (John Wiley & Sons, 2008); Ahuja, S., Chiral Separation Methods for Pharmaceutical and Biotechnological Products (John Wiley & Sons, 2011).

[0035] "Tautomers" refer to the isomers of a compound that are in equilibrium based on proton transfer. The concentration of isomers will depend on the environment in which the compound is found and can vary depending on, for example, whether the compound is a solid or in an organic or aqueous solution. For example, in aqueous solution, pyrazole can exhibit the following isomers, which are referred to as tautomers of each other: .

[0036] As will be readily understood by those skilled in the art, a wide variety of functional groups and other structures can exhibit tautomerism, and all tautomers of the compounds of the present invention are within the scope of this disclosure.

[0037] It should also be noted that the compounds disclosed herein may contain atomic isotopes in non-natural proportions at one or more atoms. For example, the compounds may be radiolabeled with radioactive isotopes, such as tritium ( 3 H), Iodine-125 ( 125 I), sulfur-35 ( 35 S) or carbon-14 ( 14 C), or isotope enrichment can be performed, for example, using deuterium (C). 2 H), carbon-13 ( 13 C) or nitrogen-15 ( 15 As used herein, an "isotope isomer" is an isotopically enriched compound. The term "isotopically enriched" means an atom having an isotopic composition different from that of a naturally occurring atom. "Isotopically enriched" can also mean a compound containing at least one atom having an isotopic composition different from that of a naturally occurring atom. The term "isotopic composition" refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically enriched compounds can be used as therapeutic agents (e.g., cancer therapeutic agents), research reagents (e.g., binding assay reagents), and diagnostic agents (e.g., in vivo imaging agents). All isotopic variants of the compounds described herein, whether or not radioactive, are intended to be covered within the scope of the embodiments provided herein. In some embodiments, isotopic isomers of the compounds disclosed herein are provided, for example, compounds enriched in deuterium, carbon-13, and / or nitrogen-15. As used herein, "deuterated" means that at least one hydrogen (H) has been deuterated (by D or 2 H represents a substitute compound, meaning that the compound is enriched for deuterium at at least one position.

[0038] It should be understood that, independent of stereoisomerism or isotopic composition, each compound disclosed herein may be provided in the form of any pharmaceutically acceptable salt discussed herein. Similarly, it should be understood that isotopic composition may vary independently of the stereoisomerism of the compounds mentioned herein. Furthermore, while the isotopic composition is limited by the elements present in the compounds disclosed herein or their salts, it may otherwise vary independently of the choice of pharmaceutically acceptable salts for those compounds.

[0039] It should be noted that if there is a difference between the described structure and the name of the structure, the described structure shall prevail.

[0040] As used herein, “treatment” means the complete or partial reduction of a disorder, disease, or symptom, or one or more symptoms associated with the disorder, disease, or symptom, or the slowing or cessation of the further development or worsening of those symptoms, or the reduction or eradication of the cause of the disorder, disease, or symptom itself. In one embodiment, the disorder is a neurodegenerative disease as described herein, or its symptoms.

[0041] As used herein, “prevention” means the following methods: delaying and / or preventing the occurrence, recurrence, or spread of all or part of a disorder, disease, or condition; preventing an individual from acquiring a disorder, disease, or condition; or reducing the risk of an individual acquiring a disorder, disease, or condition. In one implementation, the disorder is a neurodegenerative disease as described herein, or a symptom thereof.

[0042] The term “effective amount” in relation to the compounds disclosed herein means the amount that is sufficient to treat or prevent the disorder, disease or ailment or its symptoms disclosed herein.

[0043] As used herein, the terms “individual” or “patient” include animals, including but not limited to animals such as cattle, monkeys, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs, and in one embodiment, mammals, and in another embodiment, humans. In one embodiment, an individual is a human who has or is at risk of having an ALK-mediated disease or symptoms thereof.

[0044] While various features of the invention may be described in the context of a single embodiment, these features may also be provided individually or in any suitable combination. Conversely, although the invention may be described herein in the context of a single embodiment for clarity, the invention may also be practiced in a single embodiment.

[0045] compound

[0046] 1. In a first aspect, the present invention provides a group of compounds, wherein said compounds are selected from: ; ; ; ; ; ; ;and ; Or a pharmaceutically acceptable salt, solvate, hydrate, eutectic, cage-like inclusion compound, polymorph or tautomer thereof, a pharmaceutically acceptable salt of said polymorph or tautomer, a stereoisomer of any of the foregoing, or a mixture thereof.

[0047] 2. In another aspect, the present invention includes the compound of embodiment 1, wherein said compound is .

[0048] 3. In another aspect, the present invention includes the compound of embodiment 1, wherein said compound is .

[0049] 4. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is .

[0050] 5. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is

[0051] 6. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is .

[0052] 7. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is .

[0053] 8. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is .

[0054] 9. In another aspect, the invention includes the compound of embodiment 1, wherein said compound is .

[0055] 10. In another aspect, the present invention includes a method for reducing ALK protein levels, said method comprising contacting cells with an effective amount of a compound of any one of embodiments 1-9 or a pharmaceutically acceptable salt, tautomer, isotope isomer or stereoisomer thereof.

[0056] 11. In another aspect, the invention includes the method of embodiment 10, wherein the cells are in an individual.

[0057] 12. In another aspect, the present invention includes a method for preventing or treating cancer in an individual, the method comprising administering to an individual in need an effective amount of a compound of any one of embodiments 1-9 or a pharmaceutically acceptable salt, tautomer, isotopic isomer or stereoisomer thereof.

[0058] 13. In another aspect, the present invention includes the method according to embodiment 12, wherein the cancer is selected from gastric cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, skin cancer, colon cancer, neuroblastoma, osteosarcoma, uterine cancer, rectal cancer, and kidney cancer.

[0059] 14. In another aspect, the present invention includes a method according to embodiment 13, wherein the cancer is selected from pancreatic ductal adenocarcinoma (PDAC), small cell lung cancer, non-small cell lung cancer (NSCLC), glioblastoma, ovarian cancer, triple-negative breast cancer, serous uterine carcinoma, Ewing's sarcoma, melanoma, colon cancer, and clear cell renal cell carcinoma (ccRCC).

[0060] 15. In another aspect, the invention includes a compound of any one of embodiments 1-9, which is used as a pharmaceutical agent.

[0061] 16. In another aspect, the invention includes a compound of any one of embodiments 9 and 15, in a method of treating cancer, said method comprising administering a therapeutically effective amount of said compound to a mammal suffering from cancer.

[0062] 17. In another aspect, the invention includes the use of a compound of any one of embodiments 1-9 and 15-16, or a pharmaceutically acceptable salt, tautomer, isotopic isomer, or stereoisomer thereof, in the preparation of a medicament for reducing ALK protein levels.

[0063] 18. In another aspect, the invention includes the use of a compound of any one of embodiments 1-9 and 15-16, or a pharmaceutically acceptable salt, tautomer, isotopic isomer, or stereoisomer thereof, in the preparation of a medicament for the prevention or treatment of cancer.

[0064] 19. In another aspect, the present invention includes the compound for use according to embodiment 18, wherein the cancer is selected from gastric cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, skin cancer, colon cancer, neuroblastoma, osteosarcoma, uterine cancer, rectal cancer, and kidney cancer.

[0065] 20. In another aspect, the present invention includes the compound for use according to embodiment 19, wherein the cancer is selected from pancreatic ductal adenocarcinoma (PDAC), small cell lung cancer, non-small cell lung cancer (NSCLC), glioblastoma, ovarian cancer, triple-negative breast cancer, serous uterine carcinoma, Ewing's sarcoma, melanoma, colon cancer, and clear cell renal cell carcinoma (ccRCC).

[0066] 21. In another aspect, the invention includes a compound for use according to any one of embodiments 16-20, wherein the use further includes administration of a therapeutically effective amount of another second active agent or supportive treatment, wherein the other second active agent is a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a tyrosine kinase inhibitor, a cytokine, an anticancer agent, an antibiotic, a COX-2 inhibitor, an immunomodulator, an immunosuppressant, a corticosteroid, or a mutant or derivative thereof with pharmacological activity thereof.

[0067] In the description herein, it should be understood that each description, variation, embodiment, or aspect of a certain part may be combined with each description, variation, embodiment, or aspect of other parts, just as each combination of multiple descriptions is listed separately and individually. For example, the R of this invention... 1 Each description, variation, implementation, or aspect provided can be related to R. 2 R 3 R 4 R 5 R 6 R 7 R 8Each description, variation, embodiment, or aspect of X, Y, YY, Z, and ZZ is combined as if each combination were listed separately and individually. It should also be understood that all descriptions, variations, embodiments, or aspects of the invention are equally applicable to other chemical formulas described in detail herein, and are given the same description as if each description, variation, embodiment, or aspect were listed separately and individually for all chemical formulas. For example, all descriptions, variations, embodiments, or aspects of Example (1) are equally applicable to any chemical formula, reaction scheme, and example described in detail herein, such as Examples (2), (3), (4), (5), (6), (7), and (8), and reaction schemes INTA to INTE, and are given the same description as if each description, variation, embodiment, or aspect were listed separately and individually for all chemical formulas.

[0068] In some embodiments, compounds selected from the compounds of Examples 1-8 and Table 1, or pharmaceutically acceptable salts thereof, are provided. Although some compounds described in this disclosure are presented as specific stereoisomers and / or non-stereochemical forms, it should be understood that any or all stereochemical forms (including any enantiomers or diastereomers) of any compound of this disclosure, as well as any tautomers or other forms, are described herein.

[0069] How to use

[0070] The embodiments disclosed herein provide methods for degrading ALK in individuals in need, methods for reducing ALK protein levels, and methods for preventing or treating diseases (such as cancer).

[0071] In one aspect, this document provides a method for degrading ALK in individuals in need, the method comprising contacting cells with an effective amount of the compound of the present invention. The degradation of ALK can be assessed and confirmed by a variety of methods known in the art. Kits and commercially available assays (including cell-based assays) can be used to determine whether ALK has been degraded and to what extent. In some embodiments, the compound of the present invention partially degrades ALK. In some embodiments, the compound of the present invention completely degrades ALK.

[0072] In some embodiments, the compounds of the present invention degrade ALK by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some embodiments, the compounds of the present invention degrade ALK by about 1-100%, 5-100%, 10-100%, 15-100%, 20-100%, 25-100%, 30-100%, 35-100%, 40-100%, 45-100%, 50-100%, 55-100%, 60-100%, 65-100%, 70-100%, 75-100%, 80 ... 5-100%, 90-100%, 95-100%, 5-95%, 5-90%, 5-85%, 5-80%, 5-75%, 5-70%, 5-65%, 5-60%, 5-55%, 5-50%, 5-45%, 5-40%, 5-35%, 5-30%, 5-25%, 5-20%, 5-15%, 5-10%, 10-90%, 20-80%, 30-70%, or 40-60%.

[0073] In some embodiments, this document provides methods for reducing ALK kinase protein levels, methods comprising contacting cells with an effective amount of the compounds of Examples 1-8. The reduction in ALK kinase protein levels can be assessed and confirmed by a variety of methods known in the art. Kits and commercially available assays (including cell-based assays) can be used to determine whether and to what extent the kinase protein levels have been reduced.

[0074] In some embodiments, the compounds of the present invention reduce ALK kinase protein levels by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some embodiments, the compounds of the present invention reduce ALK kinase protein levels by about 1-100%, 5-100%, 10-100%, 15-100%, 20-100%, 25-100%, 30-100%, 35-100%, 40-100%, 45-100%, 50-100%, 55-100%, 60-100%, 65-100%, 70-100%, 75-100%, 80-100%. %, 85-100%, 90-100%, 95-100%, 5-95%, 5-90%, 5-85%, 5-80%, 5-75%, 5-70%, 5-65%, 5-60%, 5-55%, 5-50%, 5-45%, 5-40%, 5-35%, 5-30%, 5-25%, 5-20%, 5-15%, 5-10%, 10-90%, 20-80%, 30-70%, or 40-60%.

[0075] In some embodiments, the EC of the compounds of the present invention was measured in an ALK degradation assay. 50 The values ​​are from about 0.0003 µM to about 3 µM, or from about 0.0003 µM to about 1 µM, or from about 0.0003 µM to about 0.05 µM. In some embodiments, the compounds of the present invention have an EC value of from about 0.001 µM to about 0.2 µM. 50 In some embodiments, the compounds of the present invention have an EC50 of about 0.2 µM to about 2 µM. 50 In some embodiments, the compounds of the present invention have an EC50 of less than 1 µM. 50 In some embodiments, the compounds of the present invention have an EC value of less than 0.5 µM, less than 0.2 µM, less than 0.05 µM, less than about 0.001 µM, or less than about 0.0003 µM. 50 value.

[0076] On the other hand, this document provides a method for treating cancer in individuals in need, the method comprising administering an effective amount of the compound of the present invention to the individual. In some embodiments, this document provides a method for preventing cancer in individuals in need, the method comprising administering an effective amount of the compound of the present invention to the individual. In some implementations, the cancer is selected from brain cancer, cervicocerebral cancer, esophageal cancer, thyroid cancer, small cell carcinoma, non-small cell carcinoma, breast cancer, lung cancer, gastric cancer, gallbladder / choleduct cancer, liver cancer, pancreatic cancer, colon cancer, rectal cancer, ovarian cancer, choriocarcinoma, endometrial cancer, cervical cancer, renal pelvis / ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, fetal cancer, Wilms' cancer, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's tumor, soft tissue sarcoma, acute leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, polycythemia vera, malignant lymphoma, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

[0077] In some embodiments, the cancer is selected from gastric cancer, lung cancer, pancreatic cancer, brain cancer, ovarian cancer, breast cancer, skin cancer, colon cancer, neuroblastoma, osteosarcoma, uterine cancer, rectal cancer, and kidney cancer. In some embodiments, the cancer is selected from pancreatic ductal adenocarcinoma (PDAC), small cell lung cancer, non-small cell lung cancer (NSCLC), glioblastoma, ovarian cancer, triple-negative breast cancer, serous uterine carcinoma, Ewing's sarcoma, melanoma, colon cancer, and clear cell renal cell carcinoma (ccRCC).

[0078] In some embodiments, administration of the compound of the present invention to an individual susceptible to cancer can prevent any symptoms of cancer in that individual (e.g., tumor growth or metastasis). In some embodiments, administration of the compound of the present invention to an individual who has not yet shown symptoms of cancer can prevent any symptoms of cancer in that individual. In some embodiments, administration of the compound of the present invention to an individual in need can reduce the extent of cancer in that individual. In some embodiments, administration of the compound of the present invention to an individual in need can stabilize cancer (prevent or delay cancer progression). In some embodiments, administration of the compound of the present invention to an individual in need can delay the onset or recurrence of cancer. In some embodiments, administration of the compound of the present invention to an individual in need can slow the progression of cancer. In some embodiments, administration of the compound of the present invention to an individual in need can provide partial remission of cancer. In some embodiments, administration of the compound of the present invention to an individual in need can provide overall remission of cancer. In some embodiments, administration of the compound of the present invention to an individual in need can reduce the dosage of one or more other drugs required to treat cancer. In some embodiments, administration of the compound of the present invention to an individual in need can enhance the effect of another drug used to treat cancer. In some embodiments, administration of the compound of the present invention to an individual in need can delay the progression of cancer. In some embodiments, administration of the compounds of the present invention to individuals in need can improve the quality of life of individuals with cancer. In some embodiments, administration of the compounds of the present invention to individuals in need can prolong the survival of individuals with cancer.

[0079] In one aspect, this article provides a method for preventing cancer in cancer-prone individuals, the method comprising administering the compound of the present invention to the individual.

[0080] In some aspects, this document provides methods for reducing the severity of cancer in an individual, the methods comprising administering the compounds of the present invention to the individual. In some embodiments, this document provides methods for stabilizing cancer in an individual, the methods comprising administering the compounds of the present invention to the individual. In some embodiments, the methods prevent the progression of cancer.

[0081] In another aspect, this article provides a method for delaying the onset or recurrence of cancer in an individual, the method comprising administering the compound of the present invention to the individual.

[0082] In some embodiments, this document provides a method for slowing cancer progression in an individual, the method comprising administering the compounds of the present invention to the individual. In some embodiments, the method provides partial remission of cancer. In some embodiments, the method provides overall remission of cancer.

[0083] In another aspect, this document provides methods for reducing the dosage of one or more other drugs required to treat cancer in an individual, the methods comprising administering the compound of the present invention to the individual. In some embodiments, this document provides methods for enhancing the effect of another drug used to treat cancer in an individual, the methods comprising administering the compound of the present invention to the individual.

[0084] This document also provides methods for delaying cancer progression in an individual, the methods comprising administering the compounds of the present invention to the individual. In some embodiments, the methods improve the quality of life of an individual with cancer. In some embodiments, the methods prolong the survival of an individual with cancer.

[0085] In some embodiments, the compounds of the present invention can be used to prepare medicaments for reducing ALK kinase protein levels. In some embodiments, the compounds of the present invention can be used to prepare medicaments for the prevention or treatment of ALK-related diseases.

[0086] The methods and uses disclosed herein may include the compounds of the invention used alone or in combination with one or more other therapies (e.g., non-pharmacological treatments or therapeutic agents).

[0087] In some embodiments, the compound used according to any one of embodiments 70-75, wherein the use further includes administration of a therapeutically effective amount of another second active agent or supportive treatment, wherein the other second active agent is a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, an anticancer agent, a tyrosine kinase inhibitor, an antibiotic, a COX-2 inhibitor, an immunomodulator, an immunosuppressant, a corticosteroid, or a mutant or derivative thereof with pharmacological activity thereof.

[0088] The compounds of the present invention can be administered before, after, or simultaneously with one or more such additional therapies. When combined, the dosage of the compounds of the present invention and the dosage of one or more additional therapies (e.g., non-pharmacological treatments or therapeutic agents) can provide a therapeutic effect (e.g., a synergistic or additive therapeutic effect). The compounds of the present invention can be administered together with other therapies (e.g., in a single pharmaceutical composition) or separately, and when administered separately, this can occur simultaneously or sequentially. Such sequential administration can be close together or spaced far apart in time.

[0089] In some embodiments, an additional therapy is the administration of agents that limit side effects (e.g., agents designed to reduce the occurrence or severity of treatment side effects). For example, in some embodiments, the compounds of the present invention may be used in combination with therapeutic agents for treating nausea. Examples of agents that can be used to treat nausea include, but are not limited to, dronabinol, granisetron, metoclopramide, ondansetron, prochlorperazine, and pharmaceutically acceptable salts thereof.

[0090] In some embodiments, one or more additional therapies include non-pharmacological treatments (e.g., surgery or radiation therapy). In some embodiments, one or more additional therapies include therapeutic agents (e.g., compounds or biologics acting as antiproliferative agents). In some embodiments, one or more additional therapies include both non-pharmacological treatments and therapeutic agents. In other embodiments, one or more additional therapies include two therapeutic agents. In further embodiments, one or more additional therapies include three therapeutic agents. In some embodiments, one or more additional therapies include four or more therapeutic agents.

[0091] Pharmaceutical Compositions and Routes of Administration

[0092] The compounds disclosed herein can be administered to an individual orally, topically, or parenterally in conventional formulations such as capsules, microcapsules, tablets, granules, powders, lozenges, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions, and emulsions.

[0093] The compounds disclosed herein can be administered to individuals orally, topically, or parenterally in conventional formulations such as capsules, microcapsules, tablets, granules, powders, lozenges, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions, and emulsions. Suitable formulations can be prepared using conventional organic or inorganic additives via common methods, such additives as excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, or calcium carbonate), binders (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylene pyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, or starch), and disintegrants (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low-substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate, or lime). The pharmaceutical composition contains calcium citrate, lubricants (e.g., magnesium stearate, light anhydrous silicate, talc, or sodium lauryl sulfate), flavoring agents (e.g., citric acid, menthol, glycine, or orange powder), preservatives (e.g., sodium benzoate, sodium bisulfite, methylparaben, or propylparaben), stabilizers (e.g., citric acid, sodium citrate, or acetic acid), suspensions (e.g., methylcellulose, polyvinylpyrrolidone, or aluminum stearate), dispersants (e.g., hydroxypropyl methylcellulose), diluents (e.g., water), and base waxes (e.g., cocoa butter, white petrolatum, or polyethylene glycol). The effective amount of the compounds of the present invention in the pharmaceutical composition can be at a level that will exert the desired effect; for example, for oral and parenteral administration, a single dose unit is from about 0.005 mg / kg body weight to about 10 mg / kg body weight.

[0094] The dosage range of the compounds of the present invention to be administered to an individual is quite wide and can be determined by a healthcare practitioner. Generally, the compounds disclosed herein can be administered one to four times daily at a dose of about 0.001 mg / kg body weight to about 10 mg / kg body weight, but the above doses can be appropriately varied according to the individual's age, weight, medical condition, and type of administration. In one embodiment, the dose is about 0.001 mg / kg body weight to about 5 mg / kg body weight, about 0.01 mg / kg body weight to about 5 mg / kg body weight, about 0.05 mg / kg body weight to about 1 mg / kg body weight, about 0.1 mg / kg body weight to about 0.75 mg / kg body weight, or about 0.25 mg / kg body weight to about 0.5 mg / kg body weight. In one embodiment, one dose is given daily. In any given case, the amount of the compounds of the present invention administered will depend on factors such as the solubility of the active ingredient, the formulation used, and the route of administration.

[0095] In some embodiments, the compounds of the present invention are administered to an individual at doses of about 0.01 mg / day to about 750 mg / day, about 0.1 mg / day to about 375 mg / day, about 0.1 mg / day to about 150 mg / day, about 0.1 mg / day to about 75 mg / day, about 0.1 mg / day to about 50 mg / day, about 0.1 mg / day to about 25 mg / day, or about 0.1 mg / day to about 10 mg / day.

[0096] In another embodiment, this document provides a unit dose formulation comprising the compound of the invention in amounts ranging from about 0.1 mg to 500 mg, about 1 mg to 250 mg, about 1 mg to about 100 mg, about 1 mg to about 50 mg, about 1 mg to about 25 mg, or about 1 mg to about 10 mg.

[0097] In one specific embodiment, this document provides a unit dose formulation comprising about 0.1 mg or 100 mg of the compound of the present invention.

[0098] In another embodiment, this document provides unit dose formulations comprising 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg, or 1400 mg of the compounds of the present invention.

[0099] The compounds of the present invention may be administered once, twice, three times, four times or more daily. As a non-limiting example, doses of 100 mg or less may be administered once daily, and doses greater than 100 mg may be administered twice daily in an amount equal to half the total daily dose.

[0100] For convenience, the compounds of the present invention can be administered orally. In one embodiment, when administered orally, the compounds of the present invention are taken with food and water. In another embodiment, the compounds of the present invention are dispersed in water or juice (e.g., apple juice or orange juice) or any other liquid and administered orally in solution or suspension form.

[0101] The compounds disclosed herein can also be applied intradermally, intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously, intranasally, epidurally, sublingually, intracerebrally, intravaginally, percutaneously, transrectally, transmucosally, by inhalation, or topically to the ear, nose, eye, or skin. The method of application is determined by the healthcare practitioner and may be partly dependent on the site of the medical condition.

[0102] In one embodiment, this document provides capsules containing the compounds of the present invention but without additional carriers, excipients or mediators.

[0103] In another embodiment, this document provides a composition comprising an effective amount of the compound of the present invention and a pharmaceutically acceptable carrier or mediator, wherein the pharmaceutically acceptable carrier or mediator may comprise excipients, diluents, or mixtures thereof. In one embodiment, the composition is a pharmaceutical composition.

[0104] The composition may be in the form of tablets (e.g., chewable tablets), capsules, solutions, parenteral solutions, lozenges, suppositories, spray-dried dispersions, and suspensions. The composition may be formulated to contain a daily dose or a suitable fraction of a daily dose in a dosing unit, which may be a single tablet or capsule or a suitable volume of liquid. In one embodiment, the solution is prepared from a water-soluble salt, such as hydrochloride. Typically, all compositions are prepared according to methods known in medicinal chemistry. Capsules may be prepared by mixing the compound with a suitable carrier or diluent and filling a suitable amount of the mixture into a capsule. Common carriers and diluents include, but are not limited to, inert powdered substances, such as many different types of starch; powdered cellulose, especially crystalline and microcrystalline cellulose; sugars, such as fructose, mannitol, and sucrose; cereal flours and similar edible powders.

[0105] Tablets can be prepared by direct compression, wet granulation, or dry granulation. Their formulations typically include diluents, binders, lubricants, disintegrants, and compounds. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or calcium sulfate, and inorganic salts (such as sodium chloride and powdered sugars). Powdered cellulose derivatives are also suitable. Typical tablet binders include substances such as starch, gelatin, and sugars such as lactose, fructose, and glucose. Natural and synthetic gums are also suitable, including gum arabic, alginate, methylcellulose, and polyvinylpyrrolidone. Polyethylene glycol, ethylcellulose, and waxes can also act as binders.

[0106] Lubricants may be necessary for tablet formulations to prevent tablets and punches from sticking to the mold. Lubricants can be selected from smooth solids (such as talc, magnesium stearate, and calcium stearate), stearic acid, and hydrogenated vegetable oils. Tablet disintegrants are substances that swell upon wetting to break up the tablet and release a compound. These include starch, clay, cellulose, alginate, and gum. More specifically, corn and potato starch, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponges, cation exchange resins, alginate, guar gum, citrus pomace, carboxymethyl cellulose, and sodium lauryl sulfate can be used. Tablets may be coated with sugar as a flavoring and sealing agent, or with a film-forming protectant to modify the tablet's dissolution properties. The composition may also be formulated into chewable tablets, for example, by using a substance such as mannitol in the formulation.

[0107] When the compounds described herein need to be administered in suppository form, typical suppository bases can be used. Cocoa butter is a conventional suppository base, which can be modified by adding wax to slightly increase its melting point. In particular, water-miscible suppository bases containing polyethylene glycol of various molecular weights are widely used.

[0108] The action of a compound can be delayed or prolonged through appropriate formulation. For example, slow-dissolving microspheres of the compound can be prepared and incorporated into tablets or capsules or as slow-release implantable devices. The technology also includes preparing microspheres with several different dissolution rates and filling capsules with mixtures of microspheres. Tablets or capsules can be coated with a film that resists dissolution over a predictable period. Even parenteral formulations can be made long-acting by dissolving or suspending the compound in an oily or emulsified medium that allows it to disperse slowly in serum.

[0109] Example

[0110] The following embodiments are provided as examples and not as limitations. Those skilled in the art can modify the steps described in the illustrative embodiments to obtain the desired product.

[0111] Salts of the compounds described herein can be prepared by standard methods, such as including an acid (e.g., TFA, formic acid, or HCl) in the mobile phase during chromatographic purification, or by stirring the product with a solution of an acid (e.g., aqueous hydrochloric acid) after chromatographic purification.

[0112] Unless otherwise stated, all reactions are carried out at room temperature.

[0113] The following abbreviations may be relevant to this application.

[0114] Abbreviation Table

[0115] Synthesis Examples

[0116] Synthesis method

[0117] The compounds described herein can be prepared using conventional organic synthesis and commercially available starting materials or the methods provided herein. By way of example, and not limitation, the compounds of Example (3) can be prepared as outlined in reaction scheme 3 and in the examples presented herein. It should be noted that those skilled in the art will know how to modify the illustrative reaction schemes and the steps described in the examples to obtain the desired products, including, for example, selecting starting materials (or racemic starting materials) with different stereochemistry to obtain the desired products with different stereochemistry.

[0118] The practice of the invention can be further understood by referring to the following embodiments, which are provided by way of illustration and not limitation.

[0119] Typically, the steps disclosed herein produce a mixture of diastereomers and / or regioisomers. In the examples and intermediates, diastereomers and / or regioisomers are sometimes not shown for convenience, but it should be understood that they may be present in the initial product mixture and separated at a later time, for example by preparative HPLC.

[0120] A mixture of diastereomers and / or regioisomers can be separated in an early stage of synthesis, and the remaining synthetic steps can be carried out with the diastereomers and / or regioisomers; or alternatively, a mixture of diastereomers and / or regioisomers can be carried forward to advance the synthesis, and separation can be achieved at a later stage as needed.

[0121] The foregoing detailed description includes paragraphs that primarily or specifically relate to specific parts or aspects of the invention. It should be understood that, for clarity and convenience, a particular feature may be relevant not only in the paragraph in which it is disclosed, but the disclosure herein includes all suitable combinations of information found in different paragraphs. Similarly, although the various figures and descriptions herein relate to specific embodiments of the invention, it should be understood that where a particular feature is disclosed in the context of a particular figure or embodiment, that feature may also be used, to the appropriate extent, in the context of another figure or embodiment, in combination with another feature, or throughout the invention.

[0122] All starting materials were prepared using the following steps or purchased from commercial suppliers such as Sigma-Aldrich, Combi-Blocks, Enamine, and eMolecules. All reagents were purchased from commercial suppliers (e.g., Sigma-Aldrich).

[0123] Furthermore, although the invention has been specifically described according to certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.

[0124] As will be apparent to those skilled in the art, the compounds disclosed below and in Table 1 can exist in various stereochemical forms. In the cases where the stereochemistry between piperidine-diketones and isoindolinones is shown in the examples and compounds in Table 1, this stereochemistry is an absolute configuration. Other stereocenters shown with stereochemistry and indicated as R or S can be relative stereochemistry. Racemates and single enantiomers were prepared according to the experimental procedures described below. In some cases, enantiomers were isolated from the racemate by a chiral SFC method to obtain individual enantiomers.

[0125] The synthesis of all the necessary cores and precursor intermediates involved in the above key steps is described in the experiments below.

[0126] intermediate synthesis

[0127] Reaction scheme INT A

[0128] Step 1: 3-Bromo-5-chloro-N-(2-methylallyl)pyridine-2-amine

[0129] A suspension of NaH (125.330 g, 3133.13 mmol, 60% purity) in DCM (3.40 L) was added to a solution of 3-bromo-2-methyl-prop-1-ene (357.9 g, 2651.11 mmol) and 3-bromo-5-chloro-pyridin-2-amine (500.0 g, 2410.10 mmol) in DMF (5 L). The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 1.5 h. Then, a saturated aqueous solution of NH4Cl was added to the resulting mixture. The mixture was extracted with DCM. The combined organic layers were washed with a saturated aqueous solution of LiCl. The organic layers were then dried over colorless Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by reversed-phase preparative HPLC (80% acetonitrile aqueous solution (formic acid)) to give 3-bromo-5-chloro-N-(2-methylallyl)pyridine-2-amine (380.0 g, yield: 60.3%) as a yellow oil. MS (ESI) m / z: 262.9 [M+H] + . 1 HNMR (400 MHz, CDCl3) δ 7.99 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 5.15 (s, 1H), 4.87-4.85 (m, 2H), 4.01 (s, 2H), 1.79 (s, 3H).

[0130] Step 2: Intermediate A, 5-chloro-3,3-dimethyl-1,2-dihydropyrrolo[2,3-b]pyridine

[0131] Et3N (88.34 mL, 458.80 mmol) and TBAB (49.24 g, 152.93 mmol) were added to a solution of 3-bromo-5-chloro-N-(2-methylallyl)pyridine-2-amine (40.00 g, 152.93 mmol) in DMF (400 mL). Then Pd(OAc)2 (0.690 g, 3.06 mmol) was added. The reaction mixture was degassed under vacuum and bubbled with nitrogen (3 cycles). The reaction mixture was stirred at 80 °C under a nitrogen atmosphere for 1 hour. Then HCO2Na (10.40 g, 152.93 mmol) was added to the reaction mixture. The resulting mixture was degassed under reduced pressure and bubbled with nitrogen (3 cycles). The reaction mixture was stirred at 80 °C under a nitrogen atmosphere for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography (20-30% ethyl acetate (in petroleum ether)). f = 0.43), yielding 5-chloro-3,3-dimethyl-1,2-dihydropyrrolo[2,3-b]pyridine (27.00 g, yield: 96.7%) as a yellow solid. MS (ESI) m / z: 183.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.68 (d, J = 2.4 Hz,1H), 7.32 (d, J = 2.0 Hz, 1H), 6.61 (s, 1H), 3.23 (s, 2H), 1.23 (s, 6H).

[0132] Reaction scheme INT B

[0133] Step 1: Racemic-trans-(2-(ethoxycarbonyl)cyclopropyl)potassium trifluoroborate

[0134] A solution of potassium trifluoro(vinyl)borate (10.00 g, 74.65 mmol) in THF (150 mL) was heated to 45 °C and bubbled with nitrogen. Then, Pd(OAc)₂ (0.083 g, 0.37 mmol) was added, followed by dropwise addition of ethyl 2-diazoacetic acid (11.78 mL, 111.98 mmol) over 2.5 hours. Another 0.083 g, 0.37 mmol of Pd(OAc)₂ was added, followed by dropwise addition of ethyl 2-diazoacetic acid (11.78 mL, 111.98 mmol) over 2 hours. The reaction mixture was stirred at 45 °C for 12 hours. The mixture was cooled to room temperature and concentrated to half its original volume under reduced pressure. Hexane (300 mL) was then added. After 10 minutes, a white solid precipitated from the solution. Acetone (150 mL) was then added to the solution. The resulting solution was evaporated to dryness under vacuum to obtain the residue. Toluene (150 mL) was added to the residue, and the resulting mixture was concentrated under reduced pressure to give a crude oil. The resulting oil was dissolved in EtOH (120 mL) at 80 °C. After 10 minutes, a precipitate formed. The suspension was filtered, and the filtrate was collected and concentrated under reduced pressure. Recrystallization from EtOH and Et₂O (10:1, 50 mL) gave racemic-trans-(2-(ethoxycarbonyl)cyclopropyl)trifluoroborate potassium (4.50 g, yield: 27.4%) as a gray solid. 1 H NMR (400 MHz, DMSO-d6) δ 3.99-3.94 (m, 2H), 3.32 (s, 3H), 1.15 (t, J = 14Hz, 3H), 1.12-1.07 (m, 1H), 0.68-0.59 (m, 1H), 0.54-0.43 (m, 1H), -0.01 - -0.11 (m, 1H).

[0135] Step 2: Racemic-trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)cyclopropane-1-carboxylic acid ethyl ester

[0136] A mixture of racemic-trans-(2-(ethoxycarbonyl)cyclopropyl)trifluoroborate (4.00 g, 18.18 mmol) and 2,3-dimethylbutane-2,3-diol (2.15 g, 18.18 mmol) in MeCN (50 mL) was mixed with K₂CO₃ (5.020 g, 36.36 mmol) and TMSCl (2.96 g, 27.27 mmol). The reaction mixture was then stirred at room temperature for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give racemic-trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)cyclopropane-1-carboxylic acid ethyl ester (4.36 g, yield: 99.9%) as a pale yellow oil, which was used directly in the next step without purification.

[0137] Step 3: Racemic-trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)cyclopropane-1-carboxylic acid

[0138] A solution of racemic trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)cyclopropane-1-carboxylic acid ethyl ester (4.36 g, 18.16 mmol) in THF (45 mL) was added to a solution of NaOH (3.630 g, 90.80 mmol) in water (3.7 mL). The mixture was then stirred at room temperature for 12 hours. Concentrated HCl (12 M, 9.08 mL, 108.95 mmol) was then added to the mixture until pH = 1. The mixture was then concentrated under reduced pressure. Acetone (50 mL) was then added to the residue. The mixture was filtered, and 2,3-dimethylbutane-2,3-diol (2.15 g, 18.16 mmol) was added to the filtrate. The mixture was then stirred at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain racemic trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)cyclopropane-1-carboxylic acid (3.800 g, yield: 98.7%), which is a light yellow semi-solid. 1 H NMR (400 MHz, DMSO-d6) δ 12.14(s, 1H), 1.52 (td, J = 4.8, 7.6 Hz, 1H), 1.17 (s, 12H), 1.05-1.01 (m, 1H), 0.84 (dt, J = 2.8, 7.6 Hz, 1H), 0.30 (ddd, J = 5.2, 7.2, 10.0 Hz, 1H).

[0139] Step 4: Intermediate B, racemic-trans-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-yl)-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborphane-2-yl)cyclopropyl] methyl ketone

[0140] To a solution of 5-chloro-3,3-dimethyl-1,2-dihydropyrrolo[2,3-b]pyridine (INT A, 1.50 g, 8.21 mmol) and racemic-trans-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborphane-2-yl)cyclopropane-1-carboxylic acid (2.50 g, 11.79 mmol) in DCM (30 mL), EDCI (2.35 g, 12.32 mmol) and DMAP (0.10 g, 0.82 mmol) were added. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. The mixture was concentrated under reduced pressure to obtain a crude residue, which was purified by semi-preparative normal-phase HPLC (column: Welch Ultimate XB-SiOH 250). 70 10 μm; mobile phase: 1-15% hexane-ethanol (0.1% ammonium hydroxide), after 15 min, yielded racemic-trans-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-yl)-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)cyclopropyl] methyl ketone (1.10 g, yield: 35.6%), as a yellow semi-solid. MS (ESI) m / z: 377.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 2.4 Hz, 1H), 7.36 (d, J =2.4 Hz, 1H), 3.90-3.80 (m, 2H), 1.50-1.46 (m, 1H), 1.34 (d, J = 7.2 Hz, 6H), 1.27 (d, J = 4.0 Hz, 12H), 1.22 (d, J = 6.4 Hz, 1H), 1.11 (dt, J = 2.8, 7.2Hz, 1H), 0.66 (ddd, J = 5.2, 7.2, 10.0 Hz, 1H).

[0141] Reaction scheme INT C

[0142] Step 1: Methyl 3-bromo-6-fluoro-2-methylbenzoate

[0143] To a solution of 3-bromo-6-fluoro-2-methylbenzoic acid (11.00 g, 47.20 mmol) in methanol (100 mL), add (trimethylsilyl)diazomethane (2 M solution, in hexane) (118.01 mL, 236.02 mmol). The mixture is then stirred at 25 °C for 2 hours. The mixture is filtered, and the filtrate is concentrated under vacuum to obtain a residue. The residue is purified by silica gel chromatography (9% ethyl acetate (in petroleum ether), R... f = 0.8), yielding methyl 3-bromo-6-fluoro-2-methylbenzoate (11.000 g, 44.52 mmol, 94.321% yield), as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.58(dd, J = 5.2, 8.8 Hz, 1H), 6.87 (t, J = 8.8 Hz, 1H), 3.96 (s, 3H), 2.41 (s,3H).

[0144] Step 2: Methyl 3-bromo-2-(bromomethyl)-6-fluorobenzoate

[0145] AIBN (6.647 g, 40.48 mmol) and NBS (8.645 g, 48.57 mmol) were added to a solution of methyl 3-bromo-6-fluoro-2-methylbenzoate (10.00 g, 40.48 mmol) in MeCN (100 mL). The mixture was then stirred at 90 °C under a nitrogen atmosphere for 12 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by normal-phase column chromatography (9% ethyl acetate (in petroleum ether), R... f = 0.75), yielding methyl 3-bromo-2-(bromomethyl)-6-fluorobenzoate (13.00 g, 39.88 mmol, 98.533% yield), as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.62 (dd, J = 5.2, 8.8 Hz, 1H), 6.98 (t, J = 8.8 Hz, 1H), 4.71 (s,2H), 3.98 (s, 3H).

[0146] Step 3: Intermediate C, racemic 5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester

[0147] To a solution of methyl 3-bromo-2-(bromomethyl)-6-fluorobenzoate (13.00 g, 39.88 mmol) in MeCN (150 mL), DIEA (20.84 mL, 119.65 mmol) and tert-butyl 4,5-diamino-5-oxo-valerate (8.870 g, 43.87 mmol) were added. The mixture was then stirred at 90 °C for 12 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the residue. The residue was purified by normal-phase column chromatography (66% ethyl acetate (in petroleum ether), R... f = 0.5), yielding racemic 5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester (16.00 g, 38.53 mmol, 96.612% yield), as a white solid. MS (ESI) m / z: 415.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 4.0, 8.4 Hz, 1H), 6.94 (t, J = 8.4 Hz, 1H), 6.79 (s,1H), 5.71 (s, 1H), 4.90 (dd, J = 6.0, 8.0 Hz, 1H), 4.50 - 4.46 (m, 1H), 4.31 - 4.26 (m, 1H), 2.31 - 2.16 (m, 3H), 2.11 - 2.03 (m, 1H), 1.34 (s, 9H).

[0148] Reaction scheme INT D

[0149] Step 1: Intermediate D, (4S)-5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester

[0150] To a solution of (4S)-4,5-diamino-5-oxo-valerate tert-butyl ester (3.412 g, 16.87 mmol) and DIEA (5.936 g, 46.02 mmol) in MeCN (50.00 mL), methyl 3-bromo-2-(bromomethyl)-6-fluorobenzoate (5.000 g, 15.34 mmol) was added. The mixture was then stirred at 90 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (5% ethyl acetate (in petroleum ether)) to give (4S)-5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester (5.000 g, yield: 78.497%) as a yellow oil. MS (ESI) m / z: 358.9 [M-55] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.86 (dd, J= 4.0, 8.4 Hz, 1H), 7.61 (s, 1H), 7.35 - 7.11 (m, 2H), 4.69 (dd, J = 4.4,10.8 Hz, 1H), 4.53 - 4.34 (m, 2H), 2.25 - 2.18 (m, 2H), 2.18 - 2.12 (m, 1H), 2.01 (s, 1H), 1.33 (s, 9H).

[0151] Reaction scheme INTE

[0152] Step 1: Methyl 3-bromo-2-(bromomethyl)benzoate

[0153] A mixture of methyl 3-bromo-2-methylbenzoate (20.00 g, 87.31 mmol, 1.00 equivalent) and NBS (23.310 g, 130.96 mmol, 1.50 equivalent) was stirred in CCl4 (100 mL) at 10 °C. AIBN (12.900 g, 78.58 mmol, 0.90 equivalent) was then added. The mixture was stirred at 80 °C under a nitrogen atmosphere for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by normal-phase column chromatography (0-20% ethyl acetate (in petroleum ether)) to give methyl 3-bromo-2-(bromomethyl)benzoate (24.790 g, 80.50 mmol, 92.2% yield) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.92 (dd, J = 1.2, 8.0 Hz, 1H), 7.86 (dd, J =1.2, 8.0 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 5.03 (s, 2H), 3.91 - 3.85 (m,3H).

[0154] Step 2: 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione

[0155] DIEA (12.59 g, 97.41 mmol, 3.00 equivalent) was added to a solution of methyl 3-bromo-2-(bromomethyl)benzoate (10.00 g, 32.47 mmol, 1.00 equivalent) and 3-aminopiperidine-2,6-dione hydrochloride (5.88 g, 35.72 mmol, 1.10 equivalent) in MeCN (100 mL). The mixture was stirred at 85 °C for 12 h. The reaction mixture was concentrated under reduced pressure to remove DIEA. The reaction mixture was then stirred at 0 °C for 30 min and filtered. The filter cake was washed with acetonitrile (20 mL) and collected to give 3-(4-bromo-1-oxoisoindoline-2-yl)piperidine-2,6-dione (7.93 g, 24.54 mmol, 75.6% yield) as a blue solid. MS (ESI) m / z: 322.9 [M+H] + . 1 H NMR (400 MHz, DMSO-d6)δ 11.03 (s, 1H), 7.91 - 7.82 (m, 1H), 7.77 (d, J = 7.2 Hz, 1H), 7.51 (t, J =7.6 Hz, 1H), 5.15 (dd, J = 5.2, 13.2 Hz, 1H), 4.47 - 4.21 (m, 2H), 2.99 -2.85 (m, 1H), 2.59 (d, J = 17.6 Hz, 1H), 2.49 - 2.40 (m, 1H), 2.06 - 1.97 (m,1H).

[0156] Step 3: 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-carboxynitrile

[0157] A mixture of 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (8.80 g, 27.23 mmol, 1.00 equivalent), dppf (3.86 g, 6.96 mmol, 0.30 equivalent), Pd2(dba)3 (2.490 g, 2.72 mmol, 0.10 equivalent), and zinc cyanide (3.200 g, 27.23 mmol, 1.00 equivalent) in DMF (50 mL) was stirred at 120 °C under a nitrogen atmosphere for 12 hours. The mixture was filtered at 100 °C to remove inorganic salts. The filtrate was then cooled to 0 °C and filtered again. The filter cake was washed with DCM (50 ml) and collected to give 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-carboxynitrile (4.50 g, 16.71 mmol, 61.4% yield) as a gray solid. MS (ESI) m / z: 270.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 11.02 (s, 1H), 8.14 (dd, J = 0.8, 7.6 Hz, 1H), 8.10 - 8.04(m, 1H), 7.74 (t, J = 7.6 Hz, 1H), 5.16 (dd, J = 5.2, 13.2 Hz, 1H), 4.80 -4.64 (m, 1H), 4.60 - 4.46 (m, 1H), 2.99 - 2.84 (m, 1H), 2.65 - 2.56 (m, 1H), 2.49 - 2.39 (m, 1H), 2.09 - 1.95 (m, 1H).

[0158] Step 4: Intermediate E, 3-(4-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione hydrochloride

[0159] Pd / C (1.50 g, 10% purity) and concentrated HCl (40 mL) were added to a solution of 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-carboxynitrile (4.50 g, 16.71 mmol, 1.00 equivalent) in MeOH (120 mL) and THF (40 mL). The mixture was then stirred at room temperature under a hydrogen atmosphere (50 Psi) for 48 hours. The mixture was filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was stirred in MeCN (10 mL) at room temperature for 1 hour. The mixture was then filtered, and the solid was collected. The solid was stirred in a solution of 50% MeOH in EtOAc (20 mL) at room temperature for 1 hour. The mixture was then filtered, and the filter cake was collected. The filter cake was stirred in water (250 ml) for 3 hours, then filtered. The filtrate was concentrated under reduced pressure to give 3-(4-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione hydrochloride (2.05 g, 6.62 mmol, 39.60% yield), as a white solid. MS (ESI) m / z: 270.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.74 (s, 3H), 7.82 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 7.2Hz, 1H), 7.64 - 7.55 (m, 1H), 5.17 (dd, J = 5.2, 13.2 Hz, 1H), 4.74 (d, J =17.4 Hz, 1H), 4.48 (d, J = 17.4 Hz, 1H), 4.07 (s, 2H), 3.02 - 2.85 (m, 1H),2.62 (d, J = 16.8 Hz, 1H), 2.38 (m, J = 4.0, 13.2 Hz, 1H), 2.07 - 1.93 (m,1H).

[0160] Example

[0161] Example 1

[0162] Reaction Scheme 1

[0163] Step 1: 5-Bromobenzo[d]isoxazole-3-amine

[0164] NH₂OH-HCl (39.09 g, 562.47 mmol) was added to a mixture of 5-bromo-2-fluorobenzyl nitrile (25.00 g, 124.99 mmol) in t-BuOH (300 mL). Then, t-BuOK (70.13 g, 624.97 mmol) was added at room temperature. The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was filtered, and the filter cake was washed with EtOAc. The filtrate was then diluted with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give 5-bromobenzo[d]isoxazol-3-amine (26.00 g, yield: 97.6%) as a white solid. MS (ESI) m / z: 213.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 2.0 Hz, 1H), 7.65 (dd, J= 2.0, 8.8 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 6.50 (s, 2H)

[0165] Step 2: 3-((5-bromobenzo[d]isoxazol-3-yl)amino)propionamide

[0166] Cs₂CO₃ (21.36 g, 65.72 mmol) was added to a solution of 5-bromobenzo[d]isoxazol-3-amine (7.00 g, 32.86 mmol) and propenamide (2.80 g, 39.43 mmol) in DMAC (70 mL). The resulting mixture was stirred at 90 °C for 12 hours. The reaction mixture was filtered, and the filter cake was washed with EtOAc. The filtrate was then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the residue. The crude residue was purified by reversed-phase column chromatography (column: 330g Flash Column Welch Ultimate XB_C18 20-40μm; 120 A; mobile phase: 30-35% acetonitrile (in water), formic acid conditions) to give 3-((5-bromobenzo[d]isoxazol-3-yl)amino)propionamide (4.153 g, yield: 44.5%) as a white solid. MS (ESI) m / z: 286.0 [M+H] + . 1H NMR(400 MHz, DMSO-d6) δ 8.13 (d, J = 2.0 Hz, 1H), 7.66 (dd, J = 2.0, 8.8 Hz,1H), 7.46 (d, J = 8.8 Hz, 1H), 7.36 (s, 1H), 7.09 (t, J = 5.6 Hz, 1H), 6.85(s, 1H), 3.48-3.40 (m, 2H), 2.45 (t, J = 6.8 Hz, 2H).

[0167] Step 3: Racemic-trans-3-((5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)amino)propionamide

[0168] A mixture of 3-((5-bromobenzo[d]isoxazol-3-yl)amino)propionamide (1.60 g, 5.63 mmol) and racemic-trans-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-yl)-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)cyclopropyl] ketone (INT B, 2.12 g, 5.63 mmol) in t-AmOH (60 mL) was added to an aqueous solution of Cs₂CO₃ (1.5 M, 11.27 mL, 16.89 mmol). The mixture was then degassed and purged with nitrogen (3 cycles). CataCXium-A-Pd-G₃ (0.485 g, 0.56 mmol) was then added under a nitrogen atmosphere. The mixture was stirred at 90 °C for 12 h. The mixture was filtered, and the filter cake was washed with EtOAc. The filtrate was then concentrated under reduced pressure to obtain the residue. The residue was purified by semi-preparative reversed-phase HPLC (column: YMC-Actus Triart C18 150). 30mm 7 μm; mobile phase: 43-73% acetonitrile + 0.225% FA (in water), after 10 minutes, yielded racemic-trans-3-((5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)amino)propionamide (0.551 g, yield: 21.5%), as a brown solid. MS (ESI) m / z: 454.2 [M+H] + . 1H NMR(400 MHz, DMSO-d6) δ 8.06 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.69(s, 1H), 7.46-7.40 (m, 1H), 7.40-7.33 (m, 2H), 6.96 (t, J = 5.6 Hz, 1H), 6.85(s, 1H), 3.98-3.86 (m, 1H), 3.81 (s, 2H), 3.43 (q, J = 6.8 Hz, 2H), 2.69-2.60(m, 1H), 2.46 (t, J = 6.8 Hz, 2H), 1.64-1.56 (m, 1H), 1.46 (ddd, J = 4.0,6.4, 8.4 Hz, 1H), 1.31 (d, J = 4.8 Hz, 6H).

[0169] Step 4: Example 1, racemic-trans-1-(5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione

[0170] Racemic-trans-3-((5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)amino)propionamide (0.536 g, 1.17 mmol) was added to a solution in MeCN (7.5 mL) with Cs₂CO₃ (1.152 g, 3.54 mmol) and CDI (0.957 g, 5.90 mmol). The resulting mixture was heated to 90 °C and stirred for 12 hours. DMF (4 mL) was added to the reaction mixture. The mixture was then filtered, and the filtrate was directly purified by semi-preparative reversed-phase column chromatography (column: Phenomenex luna C18 150). 25 10 μm; mobile phase: 42-72% acetonitrile + 0.1% TFA (in water), after 11 min, yielded racemic-trans-1-(5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (0.276 g, yield: 49%). MS (ESI) m / z: 480.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ 10.92 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz,1H), 7.68 - 7.64 (m, 2H), 7.55 (dd, J = 2.0, 8.8 Hz, 1H), 4.09 - 4.02 (m,3H), 3.82 (s, 2H), 2.82 - 2.77 (m, 2H), 2.69 - 2.64 (m, 1H), 1.625 - 1.61 (m,1H), 1.47 - 1.42 (m, 1H), 1.31 (d, J = 2.4 Hz, 6H).

[0171] Examples 2 and 3

[0172] Reaction schemes 2 and 3

[0173] Step 1: Examples 2 and 3, 1-(5-((1R) ,2R )-2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione and 1-(5-((1S ,2S )-2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione

[0174] A sample of racemic-trans-1-(5-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Example 1, 0.276 g) was separated by chiral SFC (column: DAICL CHIRALPAK AD (250 mm)). 30 mm, 10 μm); mobile phase: 50% CO2-i-PrOH / ACN, eluted for 3.0 min to obtain each enantiomer (see faster and slower elution peaks below).

[0175] The faster elution peak was further purified by semi-preparative reversed-phase HPLC (column: Phenomenex luna C18 150). 25 10µm; mobile phase: 45-75% acetonitrile + 0.1% TFA (in water), after 9 minutes, 1-(5-((1R) was obtained. ,2R 2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Example 2, 82.0 mg, yield: 14.5%, 99.1% ee), is a white solid. MS (ESI) m / z: 480.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 10.94 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.70-7.63 (m, 2H), 7.55 (dd, J= 1.6, 8.8 Hz, 1H), 4.12-3.97 (m, 3H), 3.81 (s, 2H), 2.79 (dt, J = 3.2, 6.4Hz, 2H), 2.71-2.65 (m, 1H), 1.68-1.58 (m, 1H), 1.45 (ddd, J = 4.0, 6.4, 8.4Hz, 1H), 1.31 (d, J = 3.6 Hz, 6H).

[0176] The slower elution peak was further purified by semi-preparative reversed-phase HPLC (column: Phenomenex luna C18 150). 25 10µm; mobile phase: 45-75% acetonitrile + 0.1% TFA (in water), after 9 minutes, 1-(5-((1S) was obtained. ,2S 2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)benzo[d]isoxazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Example 3, 83.4 mg, yield: 14.7%, 98.5% ee), is a white solid. MS (ESI) m / z: 480.2 [M+H] + . 1H NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.70-7.62 (m, 2H), 7.55 (dd, J= 1.6, 8.8 Hz, 1H), 4.13-3.97 (m, 3H), 3.86-3.78 (m, 2H), 2.85-2.75 (m, 2H), 2.71-2.65 (m, 1H), 1.67-1.58 (m, 1H), 1.45 (ddd, J = 3.6, 6.4, 8.4 Hz, 1H),1.31 (d, J = 3.6 Hz, 6H).

[0177] Example 4

[0178] Reaction scheme 4

[0179] Step 1: Racemic-trans-5-amino-4-[7-fluoro-1-oxo-4-[2-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl]isoindoline-2-yl]-5-oxo-valerate tert-butyl ester

[0180] Add racemic-trans-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-yl)-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborphane-2-yl)cyclopropyl] methyl ketone (INT B, 0.125 g, 0.33 mmol), racemic-5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester (INT C, 0.207 g, 0.50 mmol), and Pd(dppf)Cl2 to a dried reaction vessel. DCM (0.027 g, 0.03 mmol) and K₂CO₃ (0.137 g, 1.00 mmol) were then added to the mixture. 1,4-Dioxane (5 mL) and water (0.5000 mL) were then added to the mixture. The reaction was bubbled with nitrogen (5 min) and stirred at 90 °C for 2 h. The mixture was concentrated under reduced pressure to obtain the residue. The residue was purified by reversed-phase preparative HPLC (50-80% acetonitrile aqueous solution (ammonium bicarbonate, for 9 minutes) to give racemic trans-5-amino-4-[7-fluoro-1-oxo-4-[2-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl]isoindoline-2-yl]-5-oxo-valerate tert-butyl ester (50 mg, 25.8% yield) as a white solid. MS (ESI) m / z: 585.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ = 8.11 (dd, J = 2.4,7.2 Hz, 1H), 7.90 (t, J = 2.8 Hz, 1H), 7.57 (br d, J = 12.4 Hz, 1H), 7.47 -7.37 (m, 1H), 7.28 - 7.10 (m, 2H), 4.71 - 4.64 (m, 1H), 4.63 - 4.44 (m, 2H), 4.06 - 3.89 (m, 1H), 3.88 - 3.76 (m, 2H), 2.55 (br s, 1H), 2.22 - 2.04 (m,3H), 2.01 - 1.83 (m, 1H), 1.64 - 1.55 (m, 1H), 1.55 - 1.42 (m, 1H), 1.37 -1.25 (m, 15H).

[0181] Step 2: Example 4, racemic-trans-3-[7-fluoro-1-oxo-4-[2-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl]isoindololin-2-yl]piperidin-2,6-dione

[0182] Racemic-trans-5-amino-4-[7-fluoro-1-oxo-4-[2-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl]isoindololin-2-yl]-5-oxovalerate tert-butyl ester (0.020 g, 0.03 mmol) was added to a solution in MeCN (2 mL) with MsOH (0.003 g, 0.03 mmol) and stirred at 90 °C for 2 hours. The mixture was then purified by reverse-phase preparative HPLC (column: Phenomenex luna C18 150). 25mm 10 μm; mobile phase: 45-75% acetonitrile + 0.225% FA (in water), after 10 min, yielded racemic-trans-3-[7-fluoro-1-oxo-4-[2-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl]isoindoline-2-yl]piperidin-2,6-dione (Example 4, 13.4 mg, 76.0% yield), as a white solid. MS (ESI) m / z: 511.2 [M+H] + . 1 HNMR (400 MHz, DMSO-d6) δ = 11.06 - 10.88 (m, 1H), 8.10 (t, J = 2.4 Hz, 1H), 7.91 (dd, J = 2.4, 8.0 Hz, 1H), 7.46-7.45 (m, 1H), 7.27 (t, J = 10.4 Hz, 1H),5.11 - 5.04 (m, 1H), 4.67 - 4.44 (m, 1H), 4.43 - 4.31 (m, 1H), 3.99 - 3.91(m, 1H), 3.86 - 3.78 (m, 2H), 3.00 - 2.80 (m, 2H), 2.02 - 1.83 (m, 1H), 1.67- 1.56 (m, 1H), 1.53 - 1.45 (m, 1H), 1.31 (s, 6H), 1.26 - 1.20 (m, 1H).

[0183] Examples 5 and 6

[0184] Reaction schemes 5 and 6

[0185] Step 1: trans-(S)-5-amino-4-(4-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester

[0186] Add racemic-trans-(5-chloro-3,3-dimethyl-2H-pyrrolo[2,3-b]pyridin-1-yl)-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborphane-2-yl)cyclopropyl] methyl ketone (INT B, 0.125 g, 0.33 mmol), (4S)-5-amino-4-(4-bromo-7-fluoro-1-oxo-isoindoline-2-yl)-5-oxo-valerate tert-butyl ester (INT D, 0.207 g, 0.50 mmol), and Pd(dppf)Cl2 to the dried reaction vessel. DCM (0.027 g, 0.03 mmol) and K2CO3 (0.137 g, 1.00 mmol) were then added to the mixture, followed by 1,4-dioxane (3 mL) and water (0.30 mL), and the mixture was bubbled with nitrogen (5 min). The reaction was then stirred at 90 °C for 12 h. The mixture was filtered and concentrated under reduced pressure to give the residue. The residue was purified by normal-phase preparative-TLC (66.7% ethyl acetate in petroleum ether), product R f =0.2, aryl bromide R f = 0.3), resulting in a crude mixture.

[0187] The crude mixture was further purified by semi-preparative reversed-phase HPLC (column: YMC-Actus Triart C18150). 30mm 7 μm; Mobile phase: 53-83% acetonitrile + 0.225% FA (in water), after 10 minutes, yielded trans-(S)-5-amino-4-(4-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)-5-oxopentanyl tert-butyl ester (0.035 g, yield: 18.0%), as a creamy white solid. MS (ESI) m / z: 585.2 [M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 2.4, 12.8Hz, 1H), 7.41 (t, J = 2.0 Hz, 1H), 7.33 (ddd, J = 4.4, 8.4, 12.4 Hz, 1H), 7.07 (t, J = 8.8 Hz, 1H), 6.42 (d, J = 17.6 Hz, 1H), 5.43-5.23 (m, 1H), 4.95-4.83 (m, 1H), 4.65-4.42 (m, 2H), 4.19-4.04 (m, 1H), 3.94 (d, J = 2.8 Hz, 2H),2.59-2.50 (m, 1H), 2.40-2.19 (m, 3H), 2.17-1.97 (m, 1H), 1.82 (qd, J = 4.4,9.2 Hz, 1H), 1.43 (d, J = 3.6 Hz, 9H), 1.39 (s, 3H), 1.37 (d, J = 1.6 Hz,3H), 1.34-1.26 (m, 1H).

[0188] Step 2: Examples 5 and 6, (S)-3-(4-((1R) ,2R )-2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)piperidine-2,6-dione and (S)-3-(4-((1S) ,2S )-2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)piperidin-2,6-dione

[0189] MsOH (0.006 g, 0.06 mmol) was added to a solution of trans-(S)-5-amino-4-(4-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester (0.035 g, 0.06 mmol) in MeCN (1 mL), and the reaction mixture was stirred at 90 °C for 2 hours. The reaction mixture was then directly purified by semi-preparative reversed-phase HPLC (column: Phenomenex luna C18150). 25 10 μm; mobile phase: 42-72% acetonitrile + 0.1% TFA (in water), after 9 min, yielded trans-(S)-3-(4-(2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindololin-2-yl)piperidin-2,6-dione (20 mg, diastereomer mixture), as a white solid. The diastereomer mixture was then separated by chiral SFC (column: DAICL CHIRALPAK OD (250 mm)). (30 mm, 10 μm); Mobile phase: 40% CO2-i-PrOH, after 6.6 minutes, a crude mixture with faster and slower elution peaks was obtained.

[0190] The crude, faster-eluting peak was further purified by semi-preparative reversed-phase HPLC (column: Phenomenex luna C18 150). 25 10µm; Mobile phase: 42-72% acetonitrile + 0.1% TFA (in water), after 9 minutes, to obtain (S)-3-(4-((1R) ,2R 2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)piperidin-2,6-dione (Example 5, 12.2 mg, yield: 81.0%, 98.7% de), is a yellow oil. MS (ESI) m / z: 511.3 [M+H] + 。 1H NMR (400 MHz, DMSO-d6) δ 11.00 (s,1H), 8.10 (d, J = 2.4 Hz, 1H), 7.92 (d, J = 2.4 Hz, 1H), 7.48 (dd, J = 4.4,8.4 Hz, 1H), 7.27 (t, J = 9.2 Hz, 1H), 5.07 (dd, J = 5.2, 13.2 Hz, 1H), 4.53-4.33 (m, 2H), 3.94 (d, J = 3.2 Hz, 1H), 3.89-3.77 (m, 2H), 2.96-2.84 (m, 1H),2.56-2.52 (m, 1H), 2.45 (s, 1H), 2.20 (dq, J = 4.8, 13.2 Hz, 1H), 1.93-1.81(m, 1H), 1.66-1.57 (m, 1H), 1.46 (ddd, J = 4.0, 6.4, 8.0 Hz, 1H), 1.32 (s,6H).

[0191] The crude, slower-eluting peak was further purified by semi-preparative reversed-phase HPLC (column: Phenomenex luna C18 150). 25 10µm; mobile phase: 42-72% acetonitrile + 0.1% TFA (in water), after 9 minutes, (S)-3-(4-((1S) was obtained. ,2S 2-(5-chloro-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)cyclopropyl)-7-fluoro-1-oxoisoindoline-2-yl)piperidin-2,6-dione (Example 6, 15.5 mg, yield: 90.6%, 99.0% de), is a yellow oil. MS (ESI) m / z: 511.3 [M+H] + 。 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s,1H), 8.10 (d, J = 2.4 Hz, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.45 (dd, J = 4.4,8.2 Hz, 1H), 7.27 (t, J = 8.8 Hz, 1H), 5.08 (dd, J = 5.2, 13.2 Hz, 1H), 4.60 (d, J = 17.6 Hz, 1H), 4.36 (d, J = 17.6 Hz, 1H), 3.96 (d, J = 4.0 Hz, 1H), 3.85-3.77 (m, 2H), 2.98-2.82 (m, 1H), 2.62-2.55 (m, 1H), 2.45-2.35 (m, 1H), 2.05-1.93 (m, 1H), 1.63-1.55 (m, 1H), 1.49 (ddd, J = 4.0, 6.4, 8.4 Hz, 1H), 1.31 (s, 6H).

[0192] Example 7

[0193] Reaction Scheme 7

[0194] Step 1: (5-Methylpyrimidin-2-yl)phenyl carbamate

[0195] To a mixture of 5-methylpyrimidin-2-amine (0.070 g, 0.640 mmol) and pyridine (0.06 mL, 0.770 mmol) in DCM (2.00 mL) at room temperature, phenyl chloroformate (0.100 g, 0.640 mmol) was added. The mixture was then stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to give (5-methylpyrimidin-2-yl)carbamate (0.070 g, yield: 47.8%) as a yellow solid. MS (ESI) m / z: 230.2 [M+H] + .

[0196] Step 2: Example 7, 1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-yl)methyl)-3-(5-methylpyrimidin-2-yl)urea

[0197] A solution of 3-(4-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione hydrochloride (INTE, 0.119 g, 0.440 mmol) and Et3N (0.18 mL, 1.310 mmol) in DMSO (1.00 mL) was added to a mixture of (5-methylpyrimidin-2-yl)carbamate (0.100 g, 0.440 mmol) in DMSO (1.00 mL). The mixture was then stirred at 50 °C for 12 hours. The reaction mixture was purified by semi-preparative reversed-phase HPLC (15% - 45% acetonitrile + 0.05% mmol formic acid (in water), for 8.5 min) to give 1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-4-yl)methyl)-3-(5-methylpyrimidin-2-yl)urea (Example 7, 39.1 mg, yield: 21.9%), as a white solid. MS (ESI) m / z: 409.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ = 11.00 (s, 1H),9.76 (s, 1H), 9.47 (t, J = 6.0 Hz, 1H), 8.43 (s, 2H), 7.63 (d, J = 7.2 Hz,1H), 7.58 - 7.46 (m, 2H), 5.14 (dd, J = 5.2, 13.2 Hz, 1H), 4.59 - 4.40 (m,4H), 2.99 - 2.86 (m, 1H), 2.70 - 2.57 (m, 1H), 2.40 - 2.30 (m, 1H), 2.18 (s,3H), 2.07 - 1.97 (m,1H).

[0198] Example 8

[0199] Those skilled in the art of organic synthesis will recognize that compounds containing benzo[d]isoxazole are chemical isomers of compounds containing benzo[c]isoxazole. Typically, benzo[c]isoxazole can be predictably prepared by reacting 2-(2-nitrophenyl)acetonitrile with a suitable acid (e.g., trifluoromethanesulfonic acid). Example 8 demonstrates a predictable preparation in this manner.

[0200]

[0201] biology

[0202] Targeted protein degradation represents a new paradigm in drug discovery, where small molecules can be used to induce novel protein-protein interactions and disrupt disease-driving target proteins. Protein degradation induction as a therapeutic strategy has been clinically validated by a class of immunomodulatory drugs developed by Celgene, including lenalidomide and pomalidomide. Eliminating disease-driving proteins can translate into therapeutic benefits derived from immunomodulatory drug therapy. Specifically, CELMoDs (including immunomodulatory drugs) have the ability to induce substrate proteins to be recruited to the CRL4CRBN E3 ubiquitin ligase and subsequently ubiquitinated. Following this, the ubiquitin-tagged protein is transported to the 26S proteasome and subsequently degraded by it.

[0203] EML4-ALK-HiBiT degradation assay:

[0204] NCI-H3122 cells (H3122 lung adenocarcinoma cell line) with a HiBiT tag at the C-terminus of ALK were used to monitor EML4-ALK degradation induced by the experimental compounds. The compounds were pre-spotted in 384-well plates (Corning 3570) at an initial concentration of 10 µM, followed by 3-fold serial dilutions for a total of 10 spots. The final DMSO concentration in the cell culture was 0.25%. 1500 cells / 25 µL / well were seeded in RPMI 1640 (Gibco #11875-085) supplemented with 10% heat-inactivated FBS (GIBCO #16140-071), 1% NEAA (Gibco #11140-050), and 1 mM sodium pyruvate (Gibco #11360-070). The plates were equilibrated at room temperature for 30 minutes and then incubated in a 37°C CO2 incubator. After incubation for 24 hours, the plate was removed from the incubator and allowed to equilibrate at room temperature for 30 minutes. Then, 25 µL of Nano-Glo HiBiT lysis reagent (Promega, N3050) prepared according to the manufacturer's recommendations was added. The plate was incubated at room temperature for 30 minutes and then read using a BMG PheraStar luminescence plate reader at a gain of 3400 and an integration time of 0.24 seconds.

[0205] To determine the EC50 of EML4-ALK degradation 50 The value is calculated using a four-parameter logistic model (S-shaped dose-response model) (FIT = (A + ((BA) / 1 + ((C / x)^D)))), where C is the inflection point (EC). 50 (where D is the correlation coefficient, and A and B are the lower and upper limits of the fit, respectively) to determine the EC of the compound. 50The value, or half-maximal effective concentration, is used in the EML4-ALK degradation assay. Ymin for each compound was calculated by normalizing the minimum point of the fitted curve relative to the culture medium control (0%) and cells treated with DMSO (100%). All EML4-ALK degradation curves were processed and evaluated using Dotmatics.

[0206] Table 1. EML4-ALK degradation data

[0207] Although the technology has been described in detail by way of illustration and examples for purposes of clarity, such description and examples should not be construed as limiting the scope of this disclosure. All disclosures of patents and scientific literature cited herein are expressly incorporated herein by reference in their entirety.

Claims

1. Selected from the following compounds: ; ; ; ; ; ; ;and ; Or a pharmaceutically acceptable salt, solvate, hydrate, eutectic, cage-like inclusion compound, polymorph or tautomer thereof, a pharmaceutically acceptable salt of said polymorph or tautomer, a stereoisomer of any of the foregoing, or a mixture thereof.

2. The compound of claim 1, wherein the compound is 。 3. The compound of claim 1, wherein the compound is 。 4. The compound of claim 1, wherein the compound is 。 5. The compound of claim 1, wherein the compound is 。 6. The compound of claim 1, wherein the compound is 。 7. The compound of claim 1, wherein the compound is 。 8. The compound of claim 1, wherein the compound is 。 9. The compound of claim 1, wherein the compound is 。 10. A method for reducing ALK protein levels, the method comprising contacting cells with an effective amount of the compound of any one of claims 1-9 or a pharmaceutically acceptable salt, tautomer, isotope isomer or stereoisomer thereof.

11. The method of claim 10, wherein the cell is in an individual.

12. A method for preventing or treating cancer in an individual, the method comprising administering to an individual in need an effective amount of a compound of any one of claims 1-9 or a pharmaceutically acceptable salt, tautomer, isotopic isomer, or stereoisomer thereof.

13. The method of claim 12, wherein the cancer is selected from gastric cancer, lung cancer, brain cancer, pancreatic cancer, ovarian cancer, breast cancer, skin cancer, colon cancer, neuroblastoma, osteosarcoma, uterine cancer, rectal cancer, and kidney cancer.

14. The method of claim 13, wherein the cancer is selected from pancreatic ductal adenocarcinoma (PDAC), small cell lung cancer, non-small cell lung cancer (NSCLC), glioblastoma, ovarian cancer, triple-negative breast cancer, serous uterine carcinoma, Ewing's sarcoma, melanoma, colon cancer, and clear cell renal cell carcinoma (ccRCC).

15. The compound according to any one of claims 1-9, used as a pharmaceutical agent.

16. The compound of any one of claims 9 and 15, in a method of treating cancer, the method comprising administering a therapeutically effective amount of the compound to a mammal suffering from cancer.

17. Use of a compound of any one of claims 1-9 and 15-16 or a pharmaceutically acceptable salt, tautomer, isotopic isomer or stereoisomer thereof in the preparation of a medicament for reducing ALK protein levels.

18. Use of a compound of any one of claims 1-9 and 15-16, or a pharmaceutically acceptable salt, tautomer, isotopic isomer, or stereoisomer thereof, in the preparation of a medicament for the prevention or treatment of cancer.

19. The compound for use according to claim 18, wherein the cancer is selected from gastric cancer, lung cancer, brain cancer, pancreatic cancer, ovarian cancer, breast cancer, skin cancer, colon cancer, neuroblastoma, osteosarcoma, uterine cancer, rectal cancer, and kidney cancer.

20. The compound for use according to claim 19, wherein the cancer is selected from pancreatic ductal adenocarcinoma (PDAC), small cell lung cancer, non-small cell lung cancer (NSCLC), glioblastoma, ovarian cancer, triple-negative breast cancer, serous uterine carcinoma, Ewing's sarcoma, melanoma, colon cancer, and clear cell renal cell carcinoma (ccRCC).

21. The compound for use according to any one of claims 16-20, wherein the use further comprises administering a therapeutically effective amount of another second active agent or supportive treatment, wherein the other second active agent is a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, a tyrosine kinase inhibitor, an anticancer agent, an antibiotic, a COX-2 inhibitor, an immunomodulator, an immunosuppressant, a corticosteroid, or a mutant or derivative thereof with pharmacological activity thereof.